Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial

Fastner, Gerd; Sedlmayer, Felix; Widder, Joachim; Metz, M.; Geinitz, Hans; Kapp, Karin S.; Fesl, Christian; Sölkner, Lidija; Greil, Richard; Jakesz, R.; Kwasny, Werner; Heck, Dietmar; Bjelic‐Radisic, Vesna; Balić, Marija; Stöger, Herbert; Wieder, Ursula; Zwrtek, Ronald; Semmler, Dagmar; Horvath, Wilfried; Melbinger-Zeinitzer, Elisabeth; Wiesholzer, Martin; Wette, Viktor; Gnant, Michael

doi:10.1016/j.ejca.2019.11.024

Cited by 27 publications

(22 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of radiation therapy in older (age ≥70 years) women with ER-positive breast cancers who are taking adjuvant endocrine therapy have shown that radiation therapy does not improve survival but can lower in-breast recurrence. 23 , 24 , 25 For older women with a life expectancy of >10 years, the panelists took a nuanced, customized approach to radiation treatment, explicitly rejecting the notion that no such patients should receive radiotherapy. In general, the Panel favored radiation treatment of tumors >2.5 cm, cases of positive axillary node(s), or tumors with adverse biological features, and favored omitting radiation treatment in patients with shorter life expectancies, and those with stage I, ER-positive cancers, who are likely to be adherent with adjuvant endocrine therapy.…”

Section: Local-regional Therapymentioning

confidence: 99%

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

et al. 2021

Self Cite

View full text Add to dashboard Cite

was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the 'state of the art' in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment asked by the audience. The theme of this year's conference was 'Customizing local and systemic therapies.' A well-organized program of pre-recorded symposia, live panel discussions and real-time panel voting results drew a worldwide audience of thousands, reflecting the farreaching impact of breast cancer on every continent. The interactive technology platform allowed, for the first time, audience members to ask direct questions to panelists, and to weigh in with their own vote on several key panel questions. A hallmark of this meeting was to focus on customized recommendations for treatment of early-stage breast cancer. There is increasing recognition that the care of a breast cancer patient depends on highly individualized clinical features, including the stage at presentation, the biological subset of breast cancer, the genetic factors that may underlie breast cancer risk, the genomic signatures that inform treatment recommendations, the extent of response before surgery in patients who receive neoadjuvant therapy, and patient preferences. This customized approach to treatment requires integration of clinical care between patients and radiology, pathology, genetics, and surgical, medical and radiation oncology providers. It also requires a dynamic response from clinicians as they encounter accumulating clinical information at the time of diagnosis and then serially with each step in the treatment plan and follow-up, reflecting patient experiences and treatment response.

show abstract

Section: Local-regional Therapymentioning

confidence: 99%

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a (hypothetical) patient with an HER2-negative, hormone receptor-positive, 1-3 cm breast carcinoma, multigene tests seem most appropriate in the presence of 1-3 affected lymph nodes (▶ Fig. 2; Supplementary Table S1, questions [16][17][18][19][20][21][22][23][24][25].…”

Section: Pathologymentioning

confidence: 99%

“…This was not felt to be the case in patients with tumours larger than 2.5 cm, in patients with a positive sentinel lymph node or in patients whose tumours displayed aggressive biological features (Supplementary Table S1 , questions 106 – 111). The only long-term data available are from three studies, in each of which the risk of intra-mammary recurrence was significantly increased after a longer follow-up (approximately 10% after 10 years), although this had no negative impact on survival rates 19 , 20 , 21 .…”

Section: Dcis and Endocrine Therapymentioning

confidence: 99%

See 1 more Smart Citation

Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel

Fehm

Stickeler

Fasching

et al. 2021

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

The continuous availability of findings from new studies repeatedly results in updated treatment recommendations and guidelines. In the case of breast carcinoma in particular, several studies have been published in the last few years that have transformed how early and advanced breast carcinoma is being treated. However, this by no means means implies that there is agreement among all experts on specific issues. It is precisely the diversity of interpretation of guidelines and study findings that reflects the constantly changing available data and its complexity, as well as the availability of new drugs. In recent years, new substances such as pertuzumab, T-DM1, neratinib and capecitabine have become available to treat patients with early stages of breast carcinoma. Furthermore, the first results on the use of CDK4/6 inhibitors for adjuvant treatment have now been published. Last but not least, the use of multigene tests to avoid the necessity of chemotherapy in certain patients is still under discussion. This review summarises the state of the data and publishes the results of the survey completed by experts at the 2021 St. Gallen Breast Cancer Conference on early-stage breast cancer.

show abstract

“…Accelerated partial breast irradiation (APBI) could be the most suitable compromise between WBI and abstention, particularly for patients older than 65–70 years. [1] , [2] . Since the early 1990′s, this approach has gained great interest in the treatment of carefully selected breast cancer and several consensus have been established in the United States and Europe for patients’ selection criteria [3] , [4] , [5] , [6] .…”

Section: Introductionmentioning

confidence: 99%

Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results

Chand-Fouché¹,

Colnard²,

Gal³

et al. 2023

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial

Cited by 27 publications

References 36 publications

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel

Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results

Contact Info

Product

Resources

About